{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T21:30:32Z","timestamp":1792963832897,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020875","name":"Universit\u00e9 de Versailles Saint-Quentin-en-Yvelines","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020875","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of the Review<\/jats:title>\n            <jats:p>Assess new options and best sequence or combination strategies for the treatment of metastatic thymic epithelial tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>Besides historical cytotoxic chemotherapy regimens, which remain standard-of-care for many patients with thymoma, new options include antiangiogenic agents and immune checkpoint inhibitors (ICIs) in the first-line setting combined with carboplatin and paclitaxel for thymic carcinoma. Antiangiogenic agents are also used in the second-line setting, possibly sequenced or combined with ICIs. With the latter, comprehensive assessment for autoimmune disorders is advised, with subsequent close clinical and biological monitoring. Precision medicine strategies may be implemented with comprehensive genomic profiling and use of targeted agents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Multidisciplinary tumor board is key to optimize the treatment pathway for patients with metastatic thymic epithelial tumors, with a need for prospective studies assessing the best combination strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11912-025-01680-4","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T03:41:03Z","timestamp":1748403663000},"page":"906-914","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Therapeutic Management of Metastatic Thymoma and Thymic Carcinoma"],"prefix":"10.1007","volume":"27","author":[{"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"1680_CR1","volume-title":"World health organization classification of tumours of the lung, pleura, Thymus and heart","author":"WHO histological classification","year":"2020","unstructured":"WHO histological classification. Of tumours of the thymus. In: Travis WB, Brambilla A, Burke AP, Marx A, Nicholson A, editors. World health organization classification of tumours of the lung, pleura, Thymus and heart. Lyon: IARC; 2020."},{"key":"1680_CR2","unstructured":"Thymic tumors. In: Brierley JD, Gosporadowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 8th Edition. Oxford: Wiley et Sons; 2017."},{"issue":"Suppl 5","key":"1680_CR3","doi-asserted-by":"publisher","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","volume":"26","author":"N Girard","year":"2015","unstructured":"Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, ESMO Guidelines Committee. Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v40\u201355.","journal-title":"Ann Oncol"},{"key":"1680_CR4","doi-asserted-by":"publisher","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","volume":"6","author":"M Girard","year":"2011","unstructured":"Girard M, Lal R, Wakelee H, et al. Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol. 2011;6:S1749\u20131755.","journal-title":"J Thorac Oncol"},{"key":"1680_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1245\/s10434-022-12461-9","volume":"30","author":"T Vandaele","year":"2023","unstructured":"Vandaele T, Van Slambrouck J, Proesmans V, et al. Hyperthermic intrathoracic chemotherapy (HITHOC) for pleural disseminated thymoma: A systematic literature review. Ann Surg Oncol. 2023;30:543\u201360.","journal-title":"Ann Surg Oncol"},{"key":"1680_CR6","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","volume":"13","author":"C Merveilleux du Vignaux","year":"2018","unstructured":"Merveilleux du Vignaux C, Dansin E, Mhanna L, et al. Systemic therapy in advanced thymic epithelial tumors: insights from the RYTHMIC prospective cohort. J Thorac Oncol. 2018;13:1762\u201370.","journal-title":"J Thorac Oncol"},{"key":"1680_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezac274","author":"A Alkaaki","year":"2022","unstructured":"Alkaaki A, Abo Al-Saud A, Di Lena, et al. Factors predicting recurrence in thymic epithelial neoplasms. Eur J Cardiothorac Surg. 2022. https:\/\/doi.org\/10.1093\/ejcts\/ezac274.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1680_CR8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1093\/ejcts\/ezt567","volume":"45","author":"PL Filosso","year":"2014","unstructured":"Filosso PL, Venuta F, Oliaro A, et al. Thymoma and inter-relationships between clinical variables: a multicentre study in 537 patients. Eur J Cardiothorac Surg. 2014;45:1020\u20137.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1680_CR9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.jtho.2017.06.072","volume":"12","author":"A Meurgey","year":"2017","unstructured":"Meurgey A, Girard N, du Merveilleux C, et al. Assessment of the ITMIG statement on the WHO histological classification and of the eighth TNM staging of thymic epithelial tumors of a series of 188 thymic epithelial tumors. J Thorac Oncol. 2017;12:1571\u201381.","journal-title":"J Thorac Oncol"},{"key":"1680_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.1447","author":"W Fang","year":"2024","unstructured":"Fang W, Girard N, Cilento V, et al. The IASLC thymic epithelial tumors staging project: proposals for the N and the M components for the forthcoming (9th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2024. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.1447.","journal-title":"J Thorac Oncol"},{"key":"1680_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/JTO.0000000000000482","volume":"10","author":"AC Roden","year":"2015","unstructured":"Roden AC, Eunhee SY, Jenkins SM, et al. Modified Masaoka stage and size are independent prognostic predictors in thymoma and modified Masaoka stage is superior to histopathologic classifications. J Thorac Oncol. 2015;10:691\u2013700.","journal-title":"J Thorac Oncol"},{"key":"1680_CR12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.jtho.2023.09.002","volume":"18","author":"E Ruffini","year":"2023","unstructured":"Ruffini E, Huang J, Cilento V, et al. The international association for the study of lung Cancer thymic epithelial tumors staging project: proposal for a stage classification for the forthcoming (Ninth) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2023;18:1655\u201371.","journal-title":"J Thorac Oncol"},{"key":"1680_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/JTO.0000000000000099","volume":"9","author":"A Rimner","year":"2014","unstructured":"Rimner A, Gomez DR, Wu AJ, et al. Failure patterns relative to radiation treatment fields for stage II-IV thymoma. J Thorac Oncol. 2014;9:403\u20139.","journal-title":"J Thorac Oncol"},{"key":"1680_CR14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/jamaoncol.2023.1175","volume":"9","author":"SG Chun","year":"2023","unstructured":"Chun SG, Rimner A, Amini A, et al. American radium society appropriate use criteria for radiation therapy in the multidisciplinary management of thymic carcinoma. JAMA Oncol. 2023;9:971\u201380.","journal-title":"JAMA Oncol"},{"key":"1680_CR15","doi-asserted-by":"crossref","unstructured":"Ackman JB, Chung JH, Walker CM et al. ACR appropriateness criteria imaging of mediastinal masses. Expert panel on thoracic imaging. J Am Coll Radiol 2021; 18(5S).","DOI":"10.1016\/j.jacr.2021.01.007"},{"key":"1680_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ejrad.2007.10.002","volume":"69","author":"N Tomiyama","year":"2009","unstructured":"Tomiyama N, Honda O, Tsubamoto M, et al. Anterior mediastinal tumors: diagnostic accuracy of CT and MRI. Eur J Radiol. 2009;69:280\u20138.","journal-title":"Eur J Radiol"},{"key":"1680_CR17","doi-asserted-by":"crossref","unstructured":"Proli C, De Sousa P, Jordan S et al. A diagnostic cohort study on the accuracy of 18-fluorodeoxyglucose ((18)FDG) positron emission tomography (PET)- CT for evaluation of malignancy in anterior mediastinal lesions: the decimal study. BMJ Open 2018; 8.","DOI":"10.1136\/bmjopen-2017-019471"},{"key":"1680_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jtcvs.2019.11.052","volume":"160","author":"J Zhao","year":"2020","unstructured":"Zhao J, Bhatnagar V, Ding L, Atay SM, David EA, McFadden PM, Stamnes S, Lechtholz-Zey E, Wightman SC, Detterbeck FC, Kim AW. A systematic review of paraneoplastic syndromes associated with thymoma: treatment modalities, recurrence, and outcomes in resected cases. J Thorac Cardiovasc Surg. 2020;160:306\u2013e31414.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"10 Suppl 4","key":"1680_CR19","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1097\/JTO.0b013e3181f1f63f","volume":"5","author":"A Marx","year":"2010","unstructured":"Marx A, Hohenberger P, Hoffmann H, et al. The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J Thorac Oncol. 2010;5(10 Suppl 4):S266\u2013272.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1680_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jtcvs.2019.08.037","volume":"159","author":"G Choe","year":"2020","unstructured":"Choe G, Ghanie A, Riely G, et al. Long-term, disease-specific outcomes of thymic malignancies presenting with de Novo pleural metastasis. J Thorac Cardiovasc Surg. 2020;159(2):705\u201314.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1680_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5761\/atcs.oa.17-00108","volume":"24","author":"E Kaba","year":"2018","unstructured":"Kaba E, Ozkan B, Erus S, Duman S, Cimenoglu B, Toker A. Role of surgery in the treatment of Masaoka stage IVa thymoma. Ann Thorac Cardiovasc Surg. 2018;24:6\u201312.","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"1680_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1749-8090-9-51","volume":"9","author":"MK Bae","year":"2014","unstructured":"Bae MK, Lee SK, Kim HY, Park SY, Park IK, Kim DJ, Chung KY. Recurrence after thymoma resection according to the extent of the resection. J Cardiothorac Surg. 2014;9:51.","journal-title":"J Cardiothorac Surg"},{"issue":"10 Suppl 4","key":"1680_CR23","doi-asserted-by":"publisher","first-page":"S348","DOI":"10.1097\/JTO.0b013e3181f20f27","volume":"5","author":"M Lucchi","year":"2010","unstructured":"Lucchi M, Mussi A. Surgical treatment of recurrent thymomas. J Thorac Oncol. 2010;5(10 Suppl 4):S348\u201351.","journal-title":"J Thorac Oncol"},{"key":"1680_CR24","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.3390\/cancers14205035","volume":"14","author":"B Chappuy","year":"2022","unstructured":"Chappuy B, Drevet G, Clermidy H, et al. Subtotal pleurectomy with intrathoracic chemo hyperthermia (HITHOC) for IVa thymomas: de Novo versus recurrent pleural disease. Cancers. 2022;14:5035.","journal-title":"Cancers"},{"key":"1680_CR25","first-page":"ivad032","volume":"36","author":"M Ried","year":"2023","unstructured":"Ried M, Hassan M, Passlick B, et al. Surgical cytoreduction and hyperthermic intrathoracic chemotherapy for thymic tumors with pleural spread is effective on survival: results from the multicentre German hyperthermic intrathoracic chemotherapy study. Interdiscip Cardiovasc Thorac Surg. 2023;36:ivad032.","journal-title":"Interdiscip Cardiovasc Thorac Surg"},{"key":"1680_CR26","doi-asserted-by":"publisher","first-page":"13549","DOI":"10.1038\/s41598-017-12909-z","volume":"7","author":"XJ Hao","year":"2017","unstructured":"Hao XJ, Peng B, Zhou Z, Yang XQ. Prospective study of stereotactic body radiation therapy for thymoma and thymic carcinoma: therapeutic effect and toxicity assessment. Sci Rep. 2017;7:13549.","journal-title":"Sci Rep"},{"key":"1680_CR27","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.21037\/jtd-19-3799","volume":"13","author":"G Pasquini","year":"2021","unstructured":"Pasquini G, Menichelli C, Pastore G, et al. Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: a retrospective review of 22 patients. J Thorac Dis. 2021;13:6373\u201380.","journal-title":"J Thorac Dis"},{"key":"1680_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40644-019-0267-8","volume":"19","author":"J Dong","year":"2019","unstructured":"Dong J, Yuan S, Chang B, Huang J, Geng X, Cai X, Hu P, Zhang B, Xia L, Wu P. An exploratory study of CT-guided percutaneous radiofrequency ablation for stage I thymoma. Cancer Imaging. 2019;19:80.","journal-title":"Cancer Imaging"},{"key":"1680_CR29","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","volume":"12","author":"PS Loehrer","year":"1994","unstructured":"Loehrer PS, Kim K, Aisner S, Livingston R, Einhorn L, Johnson D, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern cooperative oncology group, Southwest oncology group, and southeastern Cancer study group. J Clin Oncol. 1994;12:1164\u20138.","journal-title":"J Clin Oncol"},{"key":"1680_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2021.11.028","volume":"162","author":"A Petat","year":"2022","unstructured":"Petat A, Dansin E, Calcagno F, et al. Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. Eur J Cancer. 2022;162:118\u201327.","journal-title":"Eur J Cancer"},{"key":"1680_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jtho.2015.09.007","volume":"11","author":"F Hirai","year":"2016","unstructured":"Hirai F, Toyozawa R, Nosaki K, Seto T. Are Anthracycline-Based regimens truly indicated to be the standard chemotherapy regimen for thymic carcinoma?? J Thorac Oncol. 2016;11:115\u201321.","journal-title":"J Thorac Oncol"},{"key":"1680_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/annonc\/mdu541","volume":"26","author":"F Hirai","year":"2015","unstructured":"Hirai F, Yamanaka T, Taguchi K, Daga H, Ono A, Tanaka K, et al. A multicenter phase II study of carboplatin and Paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol. 2015;26:363\u20138.","journal-title":"Ann Oncol"},{"key":"1680_CR33","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","volume":"14","author":"G Giaccone","year":"1995","unstructured":"Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and Etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European organization for research and treatment of Cancer lung Cancer cooperative group. J Clin Oncol. 1995;14:814\u201320.","journal-title":"J Clin Oncol"},{"key":"1680_CR34","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.annonc.2024.06.002","volume":"35","author":"C Proto","year":"2024","unstructured":"Proto C, Ganzinelli M, Manglaviti S, et al. Efficacy and safety of ramucirumab plus carboplatin and Paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671). Ann Oncol. 2024;35:817\u201326.","journal-title":"Ann Oncol"},{"key":"1680_CR35","doi-asserted-by":"crossref","unstructured":"Mimori T, Shukuya T, Goto V, et al. Efficacy and safety of Atezolizumab plus carboplatin and Paclitaxel in patients with advanced or recurrent thymic carcinoma: MARBLE phase II study (JTD2101). ESMO Asia; 2024.","DOI":"10.1016\/j.annonc.2024.10.657"},{"key":"1680_CR36","first-page":"100738","volume":"5","author":"AS Tsao","year":"2024","unstructured":"Tsao AS, Hsieh MH, Koczywas M, et al. S1701, A randomized phase 2 trial of Carboplatin-Paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma. JTO Clin Res Rep. 2024;5:100738.","journal-title":"JTO Clin Res Rep"},{"key":"1680_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.cllc.2024.02.002","volume":"25","author":"Y Okuma","year":"2024","unstructured":"Okuma Y, Nomura S, Sakakibara-Konishi J, et al. Artemis: A multicenter, Open-Label, Single-Arm, phase II study to evaluate the efficacy and safety of First-Line Carboplatin\/Paclitaxel\/Lenvatinib\/Pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas. Clin Lung Cancer. 2024;25:389\u201394.","journal-title":"Clin Lung Cancer"},{"key":"1680_CR38","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2217\/fon.14.144","volume":"10","author":"G Palmieri","year":"2014","unstructured":"Palmieri G, Buonerba C, Ottaviano M, Federico P, Calabrese F, Arx CV, et al. Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial. Future Oncol. 2014;10:2141\u20137.","journal-title":"Future Oncol"},{"key":"1680_CR39","doi-asserted-by":"publisher","first-page":"7079","DOI":"10.1200\/jco.2006.24.18_suppl.7079","volume":"24","author":"PJ Loehrer","year":"2006","unstructured":"Loehrer PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol. 2006;24:7079.","journal-title":"J Clin Oncol"},{"key":"1680_CR40","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.jtho.2018.07.094","volume":"13","author":"OB Gbolahan","year":"2018","unstructured":"Gbolahan OB, Porter RF, Salter JT, Yiannoutsos C, Burns M, Chiorean EG, et al. A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma. J Thorac Oncol. 2018;13:1940\u20138.","journal-title":"J Thorac Oncol"},{"key":"1680_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2016.06.020","volume":"99","author":"M Bluthgen","year":"2016","unstructured":"Bluthgen M, Boutros C, Fayard F, Remon J, Planchard D, Besse B. Activity and safety of oral Etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience. Lung Cancer. 2016;99:111\u20136.","journal-title":"Lung Cancer"},{"key":"1680_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","volume":"16","author":"A Thomas","year":"2015","unstructured":"Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16:177\u201386.","journal-title":"Lancet Oncol"},{"key":"1680_CR43","doi-asserted-by":"publisher","first-page":"107557","DOI":"10.1016\/j.lungcan.2024.107557","volume":"191","author":"S Niho","year":"2024","unstructured":"Niho S, Sato J, Satouchi M, et al. Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: results from the multicenter, phase 2 REMORA trial. Lung Cancer. 2024;191:107557.","journal-title":"Lung Cancer"},{"issue":"3","key":"1680_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol March. 2018;19(3):347\u201355.","journal-title":"Lancet Oncol March"},{"key":"1680_CR45","doi-asserted-by":"publisher","first-page":"101576","DOI":"10.1016\/j.esmoop.2023.101576","volume":"8","author":"N Girard","year":"2023","unstructured":"Girard N, Ponce Aix S, Cedres S, Berghmans T, Burgers S, Toffart A-C, et al. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open June. 2023;8:101576.","journal-title":"ESMO Open June"},{"key":"1680_CR46","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","volume":"29","author":"C Fenioux","year":"2023","unstructured":"Fenioux C, Abbar B, Boussouar S, et al. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med. 2023;29:3100\u201310.","journal-title":"Nat Med"},{"key":"1680_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2022.12.005","volume":"180","author":"J Remon","year":"2023","unstructured":"Remon J, Villacampa G, Facchinetti F, Di Maio M, Marcuse F, Tiseo M, et al. Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumors: A meta-analysis. Eur J Cancer. 2023;180:117\u201324.","journal-title":"Eur J Cancer"},{"key":"1680_CR48","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","volume":"23","author":"F Conforti","year":"2022","unstructured":"Conforti F, Zucali PA, Pala L, Catania C, Bagnardi V, Sala I, et al. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncol Oct. 2022;23:1287\u201396.","journal-title":"Lancet Oncol Oct"},{"key":"1680_CR49","doi-asserted-by":"crossref","unstructured":"Remon J, Bironzo P, Girard N et al. Lenvatinib plus pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma: PECATI, single arm phase II clinical trial. ESMO 2024.","DOI":"10.1016\/S1470-2045(25)00300-6"},{"key":"1680_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","volume":"60","author":"AM Marchevsky","year":"2017","unstructured":"Marchevsky AM, Walts AE. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus. Hum Pathol. 2017;60:16\u2013232.","journal-title":"Hum Pathol"},{"key":"1680_CR51","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/oncolo\/oyac115","volume":"27","author":"N Girard","year":"2022","unstructured":"Girard N, Basse C, Schrock A, et al. Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers. Oncologist. 2022;27:919\u201329.","journal-title":"Oncologist"},{"key":"1680_CR52","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","volume":"33","author":"M Radovich","year":"2018","unstructured":"Radovich M, Pickering CR, Felau I, et al. The integrated genomic landscape of thymic epithelial tumors. Cancer Cell. 2018;33:244\u201358.","journal-title":"Cancer Cell"},{"key":"1680_CR53","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1093\/annonc\/mdr626","volume":"23","author":"L Schirosi","year":"2012","unstructured":"Schirosi L, Nannini N, Nicoli D, et al. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol. 2012;23:2409\u201314.","journal-title":"Ann Oncol"},{"key":"1680_CR54","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2147\/OTT.S81558","volume":"8","author":"G Spitaleri","year":"2015","unstructured":"Spitaleri G, Biffi R, Barberis M, Fumagalli C, Toffalorio F, Catania C, Noberasco C, Lazzari C, de Marinis F, De Pas T. Inactivity of Imatinib in Gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K). Onco Targets Ther. 2015;8:1997\u20132003.","journal-title":"Onco Targets Ther"},{"key":"1680_CR55","first-page":"e20588","volume":"13","author":"H Salame","year":"2021","unstructured":"Salame H, Mckey R, Ballout M, Saad W. The first reported case of neurotrophic tyrosine receptor kinase Fusion-Positive thymoma treated successfully with entrectinib. Cureus. 2021;13:e20588.","journal-title":"Cureus"},{"key":"1680_CR56","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","volume":"11","author":"AT Alberobello","year":"2016","unstructured":"Alberobello AT, Wang Y, Beerkens FJ, et al. PI3K as a potential therapeutic target in thymic epithelial tumors. J Thorac Oncol. 2016;11:1345\u201313569.","journal-title":"J Thorac Oncol"},{"key":"1680_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41698-024-00518-9","volume":"8","author":"M Tagliamento","year":"2024","unstructured":"Tagliamento M, Morfouace M, Loizides C, et al. EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers. NPJ Precis Oncol. 2024;8:37.","journal-title":"NPJ Precis Oncol"},{"key":"1680_CR58","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","volume":"36","author":"PA Zucali","year":"2018","unstructured":"Zucali PA, De Pas T, Palmieri G, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with Cisplatin-Based chemotherapy. J Clin Oncol. 2018;36:342\u20139.","journal-title":"J Clin Oncol"},{"key":"1680_CR59","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jtho.2022.10.008","volume":"18","author":"HA Jung","year":"2023","unstructured":"Jung HA, Kim M, Kim HS, et al. A phase 2 study of Palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21). J Thorac Oncol. 2023;18:223\u201331.","journal-title":"J Thorac Oncol"},{"key":"1680_CR60","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/cancers14030774","volume":"14","author":"L Montella","year":"2022","unstructured":"Montella L, Ottaviano M, Morra R, Pietroluongo E, De Placido P, Tortora M, Sorrentino C, Facchini G, De Placido S, Giuliano M, Palmieri G. The Never-Ending history of octreotide in thymic tumors: A vintage or A contemporary drug?? Cancers (Basel). 2022;14:774.","journal-title":"Cancers (Basel)"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01680-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:00:09Z","timestamp":1757174409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01680-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01680-4","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"20 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research grants\/support from Abbvie, Amgen, AstraZeneca, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merk Serono, Merck Sharp & Dohme, Novartis, Sanofi, Sivan; Consultative services for Abbvie, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Ipsen Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merck Sharp & Dohme, Mirati, Novartis, Pfizer, Pierre Fabre, Sanofi, Sivan Takeda; Participation on a data safety monitoring board for Hoffmann-La Roche; Employment of a family member with AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}